Sonis Photography / Shutterstock.com

1 April 2025NewsAmericasMarisa Woutersen

Patent cliff: 5 blockbusters running out of road

MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Novartis and MSN feud intensifies after Fed Circ denies rehearing

27 March 2025 Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.

Regeneron edges closer to Eylea market exclusivity amid biosimilar threats

6 March 2025 New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.

More on this story

Novartis and MSN feud intensifies after Fed Circ denies rehearing

27 March 2025 Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.

Regeneron edges closer to Eylea market exclusivity amid biosimilar threats

6 March 2025 New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.

More on this story

Novartis and MSN feud intensifies after Fed Circ denies rehearing

27 March 2025 Both parties write to district court hours after Court of Appeals denies rehearing | MSN maintains that the Entresto patent should be delisted from the Orange Book | Novartis urges injunction to block generic version of heart treatment before regulatory gap closes.

Regeneron edges closer to Eylea market exclusivity amid biosimilar threats

6 March 2025 New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows intense scrutiny during Federal Circuit oral arguments | Decision follows similar rulings against Samsung Bioepis and Formycon.

More features

Herbert Smith Freehills expands German tech patent team

‘Always new twists’: Bayer legal team on defending a $4bn drug

Novartis and MSN feud intensifies after Fed Circ denies rehearing

EU court signals tough stance on ‘pay-for-delay’ pharma deals

Panitch Schwarze hires experienced ex-USPTO examiner

Fed Circ affirms generic’s litigation costs of $12m are tax-deductible

Genmab fights claim over 'secrets theft' behind $1.8bn takeover

Interpreting the SPC manufacturing waiver: EU courts diverge